ARTICLE | Top Story
ReoPro shows no benefit in ACS
August 28, 2000 7:00 AM UTC
In the international 7,800-patient Phase III GUSTO IV-ACS trial conducted by Johnson & Johnson (JNJ) and partner Eli Lilly (LLY), the combined end point of death or myocardial infarction at 30 days wa...